Quarterly ResultMay 13, 2026, 09:07 AM
Canton Strategic Q1 Net Loss $(47.3M); Digital Assets $541.6M
AI Summary
Canton Strategic Holdings reported a net loss of $(47.3) million for Q1 2026, significantly wider than the $(2.5) million loss in Q1 2025, primarily due to increased general and administrative expenses and a $(15.0) million unrealized loss from digital asset holdings. The company continued its digital asset treasury strategy, increasing its Canton Coin holdings to $541.6 million. Financing activities provided $87.0 million in cash, largely from equity offerings, supporting a substantial increase in cash reserves to $41.5 million. Additionally, its biotech subsidiary, Gravitas, received positive FDA feedback for its GV104 development candidate.
Key Highlights
- Net loss for Q1 2026 widened to $(47.3) million from $(2.5) million in Q1 2025.
- General and administrative expenses surged to $36.6 million in Q1 2026 from $2.0 million in Q1 2025.
- Reported an unrealized loss of $(15.0) million from digital asset holdings in Q1 2026.
- Digital asset holdings (Canton Coin) increased to $541.6 million as of March 31, 2026.
- Cash and cash equivalents rose to $41.5 million at March 31, 2026, from $17.0 million at December 31, 2025.
- Net cash provided by financing activities was $87.0 million, driven by $90.4 million from equity offerings.
- Gravitas' GV104 received positive FDA feedback for 505(b)(2) NDA submission for PrHPO.